Meet the Dirt Cheap 6.4%-Yielding Dividend Stock That's Beating the Market in 2026

Altria Group (MO) has returned ~24% in 2026 vs ~14% for the S&P 500, but shares pulled back from as high as $77.06 to the mid-$60s after its Q2 2026 release. The quarter showed only 1.2% net revenue growth to $5.35B, with GAAP EPS of $1.37 (-2.8% YoY) missing analyst estimates, alongside continued declines in U.S. cigarette consumption. While MO still screens inexpensive at ~12x forward earnings and a 6.4% forward dividend yield, the article flags risk that earnings momentum could fail—turning the stock into a “value-and-yield trap”—even as it announced a 4.7% dividend raise and a manufacturing agreement with Philip Morris International.

Analysis

MO is behaving like a classic yield-duration equity: the multiple looks cheap until the market concludes the payout is being funded by a shrinking terminal earnings base. The key mechanism is not current cash flow, but whether pricing can keep outrunning volume declines without accelerating down-trading, illicit substitution, or share loss in next-gen nicotine. If that bridge weakens, the stock can de-rate fast because dividend buyers are less tolerant of earnings volatility than growth investors.

The cleaner relative winner is PM. Any outsourcing or manufacturing tie-up that improves utilization for MO helps the industry’s supply chain, but it does not fix MO’s strategic deficit; PM owns the higher-quality nicotine optionality and can use third-party capacity to preserve speed and capex discipline. That widens the long-term quality gap between the two names, and in staples that often translates into multiple divergence before operating divergence fully shows up.

The market may be underpricing how little has to go wrong for MO’s yield story to crack: one or two quarters of weaker earnings coverage, softer pricing power, or no visible share gains in oral nicotine would likely re-open dividend safety questions. Near term, the risk is a slow bleed rather than a crash; over 6-18 months, the bigger issue is whether MO becomes a classic ex-growth utility with tobacco exposure. The contrarian view is that PM, not MO, is the higher-conviction ‘value’ name here because it has more credible reinvestment runway and less dependence on financial engineering to defend the stock.

Key Decisions for Investors

• Long PM / short MO as a 3-6 month relative-value pair; thesis is quality-multiple divergence as PM’s nicotine mix improves while MO’s payout story becomes more fragile. Falsify if MO stabilizes earnings coverage for two consecutive quarters or PM’s oral nicotine growth decelerates sharply.
• Avoid fresh long MO initiations ahead of the next earnings cycle unless you have high confidence in volume stabilization; the yield is only attractive if dividend coverage remains intact. Treat a guide-down in EPS or payout ratio expansion as the main downside trigger.
• Buy PM on pullbacks for a 6-12 month horizon, or express via a modest call spread if you want convexity without full equity risk; the upside comes from sustained category leadership and better capital efficiency than peers.
• If already long MO for income, consider a covered-call overlay into strength to monetize the yield while capping downside from a possible de-rating; this is a better structure than owning outright if you are uncertain on next-gen nicotine traction.
• Set an alert on U.S. cigarette volume trends and Altria share in oral nicotine over the next 1-2 quarters; if neither improves, the thesis shifts from ‘cheap’ to ‘value trap’ and should be reduced.